With Global Horizon, Chinese Angle strategy, BOCG strives to support true innovation and disruptive technology of life science.
Accumulated 100+ years’ experience and US$ 1+ billion proven record, the BOCG veteran team builds its office and franchise in Shenzhen, Shanghai, Hong Kong, and Gothenburg of Sweden, and extensive networks and footprint in Greater China, Asia, USA and Europe.
A signatory to the UN PRI and committed to promoting sustainable development and impact investment.
Recently, BOCG's portfolio company, Innorna, announces that China National Medical Products Administration (NMPA) has granted a Drug Clinical Trial Approval Notice for its self-developed Herpes Zoster (HZ) mRNA vaccine IN001; meanwhile, U.S. FDA orphan drug designation granted to IN022 for the Treatment of Homocystinuria after it was granted rare pediatric disease designatio.
On July 12, 2024, Mr. Frank Yang, founding partner & CEO of Blue Ocean Capital Group, was invited by the HK Bio-Med Innotech Association and the Hong Kong Productivity Council to lecture in Hong Kong for entrepreneurs, scientists, and managers in the biopharmaceutical industry.
BOCG's portfolio company Innorna has been granted the U.S. FDA Rare Pediatric Disease Designation (RPDD) for IN022, their investigational therapy for treating classic homocystinuria (HCU).
